NextCure
NXTC----
NextCure (NXTC)
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company’s product candidate is the LNCB74, a B7-...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
NextCure Analyst Rating
View MoreForecast & Rating
Jul 15, 2026Price forecast
$20.00371.70%
Forecast & RatingStrong buy
3analysts
- Strong buy66.67%
- Buy33.33%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- prnewswire · 9 hours ago
16:38 ETHalper Sadeh LLC is Investigating Whether VEEE, NXTC, TCBK, FHB are Obtaining Fair Deals for their Shareholders
- Global Report · 20 hours ago
Clorox Shakeup and NextCure Merger Underscore Mid-2026 Corporate Overhauls
- prnewswire · 2 days ago, 01:05 PM
14:04 ET$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--VEEE, NXTC, TCBK, and FHB
- Global Report · 2 days ago, 04:18 AM
Airbus and ResMed Lead a Wave of Corporate Overhauls in Latest Strategy Shifts
- PR Newswire · Jul 21 at 01:51 PM
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?
- US Stock Market Update · Jul 16 at 01:51 PM
NextCure (NXTC) falls 7% during regular trading to $6.14
